ASLAN Pharmaceuticals gets delisting notice from Nasdaq
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
ASLAN Pharmaceuticals to be delisted from Nasdaq due to non-compliance with bid price and stockholder equity requirements.
Read at seekingalpha.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
CTMX | CytomX Therapeutics | 12.84 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 | ||||
ADAG | Adagene | 6.39 | ||||
NAMS | NewAmsterdam Pharma | 1.73 | ||||
ACRV | Acrivon Therapeutics, | 0.13 | ||||
AGIO | Agios Pharm | 0.02 | ||||
IVA | Inventiva | 0.38 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
AVTE | Aerovate Therapeutics | 1.50 | ||||
GPCR | Structure Therapeutics | 2.03 | ||||
ASMB | Assembly Biosciences | 2.09 | ||||
CMPX | Compass Therapeutics | 2.41 | ||||
CGEM | Cullinan Oncology | 2.81 | ||||
TIL | Instil Bio | 2.86 | ||||
GLUE | Monte Rosa | 3.52 | ||||
IOBT | IO Biotech | 4.44 | ||||
MLYS | Mineralys Therapeutics, | 4.60 | ||||
ERAS | Erasca | 4.95 | ||||
ANTX | AN2 Therapeutics | 6.25 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |